Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Nocturnal respiratory rate predicts ICD benefit: A prospective, controlled, multicentre cohort study

M. Dommasch, A. Steger, P. Barthel, KM. Huster, A. Müller, D. Sinnecker, KL. Laugwitz, T. Penzel, A. Lubinski, P. Flevari, M. Harden, T. Friede, S. Kääb, B. Merkely, C. Sticherling, R. Willems, HV. Huikuri, A. Bauer, M. Malik, M. Zabel, G....

. 2021 ; 31 (-) : 100695. [pub] 20201221

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21010208

Background: Implantable cardioverter defibrillators (ICDs) prevent sudden cardiac death. ICD implantation decisions are currently based on reduced left ventricular ejection fraction (LVEF≤35%). However, in some patients, the non-arrhythmic death risk predominates thus diminishing ICD-therapy benefits. Based on previous observations, we tested the hypothesis that compared to the others, patients with nocturnal respiratory rate (NRR) ≥18 breaths per minute (brpm) benefit less from prophylactic ICD implantations. Methods: This prospective cohort study was a pre-defined sub-study of EU-CERT-ICD trial conducted at 44 centers in 15 EU countries between May 12, 2014, and September 6, 2018. Patients with ischaemic or non-ischaemic cardiomyopathy were included if meeting primary prophylactic ICD implantation criteria. The primary endpoint was all-cause mortality. NRR was assessed blindly from pre-implantation 24-hour Holters. Multivariable models and propensity stratification evaluated the interaction between NRR and the ICD mortality effect. This study is registered with ClinicalTrials.gov (NCT0206419). Findings: Of the 2,247 EU-CERT-ICD patients, this sub-study included 1,971 with complete records. In 1,363 patients (61.7 (12) years; 244 women) an ICD was implanted; 608 patients (63.2 (12) years; 108 women) were treated conservatively. During a median 2.5-year follow-up, 202 (14.8%) and 95 (15.6%) patients died in the ICD and control groups, respectively. NRR statistically significantly interacted with the ICD mortality effect (p = 0.0070). While the 1,316 patients with NRR<18 brpm showed a marked ICD benefit on mortality (adjusted HR 0.529 (95% CI 0.376-0.746); p = 0.0003), no treatment effect was demonstrated in 655 patients with NRR≥18 brpm (adjusted HR 0.981 (95% CI 0.669-1.438); p = 0.9202). Interpretation: In the EU-CERT-ICD trial, patients with NRR≥18 brpm showed limited benefit from primary prophylactic ICD implantation. Those with NRR<18 brpm benefitted substantially. Funding: European Community's 7th Framework Programme FP7/2007-2013 (602299).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21010208
003      
CZ-PrNML
005      
20210715081426.0
007      
ta
008      
210413s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.eclinm.2020.100695 $2 doi
035    __
$a (PubMed)33554086
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Dommasch, Michael $u Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, Technical University of Munich, Munich, Germany
245    10
$a Nocturnal respiratory rate predicts ICD benefit: A prospective, controlled, multicentre cohort study / $c M. Dommasch, A. Steger, P. Barthel, KM. Huster, A. Müller, D. Sinnecker, KL. Laugwitz, T. Penzel, A. Lubinski, P. Flevari, M. Harden, T. Friede, S. Kääb, B. Merkely, C. Sticherling, R. Willems, HV. Huikuri, A. Bauer, M. Malik, M. Zabel, G. Schmidt, EU-CERT-ICD investigators
520    9_
$a Background: Implantable cardioverter defibrillators (ICDs) prevent sudden cardiac death. ICD implantation decisions are currently based on reduced left ventricular ejection fraction (LVEF≤35%). However, in some patients, the non-arrhythmic death risk predominates thus diminishing ICD-therapy benefits. Based on previous observations, we tested the hypothesis that compared to the others, patients with nocturnal respiratory rate (NRR) ≥18 breaths per minute (brpm) benefit less from prophylactic ICD implantations. Methods: This prospective cohort study was a pre-defined sub-study of EU-CERT-ICD trial conducted at 44 centers in 15 EU countries between May 12, 2014, and September 6, 2018. Patients with ischaemic or non-ischaemic cardiomyopathy were included if meeting primary prophylactic ICD implantation criteria. The primary endpoint was all-cause mortality. NRR was assessed blindly from pre-implantation 24-hour Holters. Multivariable models and propensity stratification evaluated the interaction between NRR and the ICD mortality effect. This study is registered with ClinicalTrials.gov (NCT0206419). Findings: Of the 2,247 EU-CERT-ICD patients, this sub-study included 1,971 with complete records. In 1,363 patients (61.7 (12) years; 244 women) an ICD was implanted; 608 patients (63.2 (12) years; 108 women) were treated conservatively. During a median 2.5-year follow-up, 202 (14.8%) and 95 (15.6%) patients died in the ICD and control groups, respectively. NRR statistically significantly interacted with the ICD mortality effect (p = 0.0070). While the 1,316 patients with NRR<18 brpm showed a marked ICD benefit on mortality (adjusted HR 0.529 (95% CI 0.376-0.746); p = 0.0003), no treatment effect was demonstrated in 655 patients with NRR≥18 brpm (adjusted HR 0.981 (95% CI 0.669-1.438); p = 0.9202). Interpretation: In the EU-CERT-ICD trial, patients with NRR≥18 brpm showed limited benefit from primary prophylactic ICD implantation. Those with NRR<18 brpm benefitted substantially. Funding: European Community's 7th Framework Programme FP7/2007-2013 (602299).
655    _2
$a časopisecké články $7 D016428
700    1_
$a Steger, Alexander $u Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, Technical University of Munich, Munich, Germany
700    1_
$a Barthel, Petra $u Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, Technical University of Munich, Munich, Germany
700    1_
$a Huster, Katharina M $u Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, Technical University of Munich, Munich, Germany
700    1_
$a Müller, Alexander $u Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, Technical University of Munich, Munich, Germany
700    1_
$a Sinnecker, Daniel $u Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, Technical University of Munich, Munich, Germany
700    1_
$a Laugwitz, Karl-Ludwig $u Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, Technical University of Munich, Munich, Germany ; German Center for Cardiovascular Research partner site Munich Heart Alliance, Munich, Germany
700    1_
$a Penzel, Thomas $u Interdisciplinary Sleep Medicine Center, Charité Universitätsmedizin Berlin, Germany
700    1_
$a Lubinski, Andrzej $u Department of Cardiology, Medical University of Lodz Hospital, Lodz, Poland
700    1_
$a Flevari, Panagiota $u Second Department of Cardiology, Attikon University Hospital, Athens, Greece
700    1_
$a Harden, Markus $u Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany
700    1_
$a Friede, Tim $u Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany ; Department of Cardiology and Pneumology, Heart Center University Medical Center Göttingen, Göttingen, Germany
700    1_
$a Kääb, Stefan $u German Center for Cardiovascular Research partner site Munich Heart Alliance, Munich, Germany ; Medizinische Klinik und Poliklinik I, Munich University Clinic, Munich, Germany
700    1_
$a Merkely, Bela $u Department of Cardiology, Semmelweis University Heart Center, Budapest, Hungary
700    1_
$a Sticherling, Christian $u University Hospital, University of Basel, Basel, Switzerland
700    1_
$a Willems, Rik $u University Hospitals of Leuven, Leuven, Belgium
700    1_
$a Huikuri, Heikki V $u Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland
700    1_
$a Bauer, Axel $u German Center for Cardiovascular Research partner site Munich Heart Alliance, Munich, Germany $u Medizinische Klinik und Poliklinik I, Munich University Clinic, Munich, Germany $u University Hospital for Internal Medicine III, Medical University Innsbruck, Innsbruck, Austria
700    1_
$a Malik, Marek $u Heart and Lung Institute, Imperial College London, London, United Kingdom ; Department of Internal Medicine and Cardiology, Medical Faculty, Masaryk University, Brno, Czech Republic
700    1_
$a Zabel, Markus $u Department of Cardiology and Pneumology, Heart Center University Medical Center Göttingen, Göttingen, Germany ; DZHK (German Center for Cardiovascular Research), partner site Göttingen, Göttingen, Germany
700    1_
$a Schmidt, Georg $u Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, Technical University of Munich, Munich, Germany $u German Center for Cardiovascular Research partner site Munich Heart Alliance, Munich, Germany
710    2_
$a EU-CERT-ICD investigators
773    0_
$w MED00200566 $t EClinicalMedicine $x 2589-5370 $g Roč. 31, č. - (2021), s. 100695
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33554086 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210413 $b ABA008
991    __
$a 20210715081425 $b ABA008
999    __
$a ind $b bmc $g 1649723 $s 1130584
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 31 $c - $d 100695 $e 20201221 $i 2589-5370 $m EClinicalMedicine $n EClinicalMedicine $x MED00200566
LZP    __
$a Pubmed-20210413

Najít záznam

Citační ukazatele

Možnosti archivace